Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung‐Hung Su, Jia‐Horng Kao, Kuo‐Chih Tseng et al.|Liver International|2016Cited by 221
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populationsMing‐Lung Yu, Wan‐Long Chuang, Pei‐Jer Chen et al.|Journal of the Formosan Medical Association|2020Cited by 98
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisYin-Chen Wang, Yi‐Hsiang Huang|Scientific Reports|2016Cited by 49